Physician profile
Bryan Curry
NPI 1740249267
$6,354.88
in general payments reported to CMS, 2019-2025
35 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $336 · 2021: $1,119 · 2022: $1,400 · 2023: $678 · 2024: $786 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Consulting Fee: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.27 |
| Consulting Fee | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,672.68 | 2021-2025 | Mycarelink, Micra, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $486.38 | 2020-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $482.86 | 2019-2022 | |
| Pfizer INC. | $474.67 | 2019-2025 | |
| Boston Scientific Corporation | $361.62 | 2021-2025 | General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $323.49 | 2019-2025 | Camzyos |
| Abbott Laboratories | $310.25 | 2019-2024 | Navitor |
| Edwards Lifesciences Corporation | $181.89 | 2019-2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $173.60 | 2019-2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.84 | 2019-2025 | Jardiance |
| Shockwave Medical, INC | $147.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $144.00 | 2020-2025 | |
| Irhythm Technologies, INC. | $135.71 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Akcea Therapeutics, INC. | $134.40 | 2019 | |
| Heartflow, INC. | $133.54 | 2023-2025 | Ffrct |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $132.44 | 2019-2022 | |
| Cvrx, INC. | $112.67 | 2022-2024 | Barostim Neo System |
| Philips North America LLC | $112.34 | 2020-2024 | (Ck4) Mcot |
| Depuy Synthes Sales INC. | $110.05 | 2021 | |
| Amarin Pharma, INC. | $101.52 | 2019 | |
| Merck Sharp & Dohme LLC | $84.63 | 2024-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $42.79 | 2022-2025 | Opsumit, Uptravi |
| Ge Healthcare | $40.15 | 2020-2023 | |
| Baxter Healthcare | $39.53 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Abiomed | $37.11 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $35.70 | 2023-2024 | Inpefa |
| Atricure, INC. | $32.84 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $31.99 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $23.59 | 2025 | Onpattro |
| My01 INC. | $20.74 | 2022 | |
| Esperion Therapeutics, INC. | $20.22 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $17.20 | 2023 | Arcalyst |
| Novo Nordisk INC | $16.01 | 2024 | Wegovy |
| Amgen INC. | $14.95 | 2025 | Repatha |
| Cardiovascular Systems INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.